...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomaterials >Invivo performance of a drug-eluting contact lens to treat glaucoma for a month
【24h】

Invivo performance of a drug-eluting contact lens to treat glaucoma for a month

机译：药物洗脱隐形眼镜治疗青光眼一个月的体内性能

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery, but achieving controlled drug release has been a significant challenge. We have developed a drug-eluting contact lens designed for prolonged delivery of latanoprost for the treatment of glaucoma, the leading cause of irreversible blindness worldwide. Latanoprost-eluting contact lenses were created by encapsulating latanoprost-poly(lactic-co-glycolic acid) films in methafilcon by ultraviolet light polymerization. Invitro and invivo studies showed an early burst of drug release followed by sustained release for one month. Contact lenses containing thicker drug-polymer films demonstrated released a greater amount of drug after the initial burst. Invivo, single contact lenses were able to achieve, for at least one month, latanoprost concentrations in the aqueous humor that were comparable to those achieved with topical latanoprost solution, the current first-line treatment for glaucoma. The lenses appeared safe in cell culture and animal studies. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications.
机译：近半个世纪以来，已经提出将隐形眼镜作为眼部药物递送的手段，但是实现受控的药物释放一直是一项重大挑战。我们已经开发了一种药物洗脱型隐形眼镜，旨在延长拉坦前列素的治疗时间，以治疗青光眼，青光眼是全球不可逆性失明的主要原因。拉坦前列素洗脱的隐形眼镜是通过紫外线聚合将拉坦前列素-聚（乳酸-乙醇酸共聚物）薄膜包封在灭多芬中而制成的。体外和体内研究表明，药物释放较早，随后持续释放了一个月。含有较厚药物-聚合物膜的隐形眼镜在初次破裂后显示释放出更多的药物。 Invivo单接触镜能够在房水中达到至少一个月的拉坦前列素浓度，该浓度与局部拉坦前列素溶液（目前用于青光眼的一线治疗）所达到的浓度相当。晶状体在细胞培养和动物研究中似乎是安全的。这种隐形眼镜设计可以潜在地用作青光眼的治疗和其他眼部药物递送应用的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号